About FDA
Number of New Bioequivalence Recommendations Posted in the month
Dictionary: The importance of bioequivalence recommendations is to make them available as quickly as possible for newly approved innovator products giving potential generic manufacturers ample time to begin to develop generic versions. By posting these recommendations publicly the agency is communicating to all interested persons at the same time on an equitable basis while also enabling transparency with the agency’s decision making.
This measure has been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 0 |
| Nov 2010 | N/A | 18 |
| Dec 2010 | N/A | 14 |
| Jan 2011 | N/A | 7 |
| Feb 2011 | N/A | 18 |
| Mar 2011 | N/A | 17 |
| Apr 2011 | N/A | 12 |
| May 2011 | N/A | 0 |
| Jun 2011 | N/A | 16 |
| Jul 2011 | N/A | 0 |
| Aug 2011 | N/A | 9 |
| Sep 2011 | N/A | 5 |
FY 2011 Total: 116
Glossary
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.
